Alcohol-associated liver disease (ALD) is a leading cause of preventable cirrhosis, hepatocellular carcinoma, and liver-related mortality, yet current laboratory and imaging tools detect only late-stage disease. This narrative review synthesizes emerging evidence on novel biomarkers that capture the multidimensional pathophysiology of ALD and discusses their utility for routine clinical practice. Traditional serum-based liver fibrosis markers (e.g., cytokeratin-18 fragments, Pro-C3, or the Enhanced Liver Fibrosis) improve non-invasive staging risk beyond aminotransferases, while elastography techniques, such as vibration-controlled transient elastography and magnetic resonance elastography, can also quantify liver stiffness with high precision. Among novel mechanistic biomarkers, genetic polymorphisms in PNPLA3, TM6SF2, MBOAT7, HSD17B13, and polygenic risk scores define lifetime risk, whereas sex-specific hormonal milieus also modify susceptibility and progression. Moreover, gut dysbiosis signatures, including reduced Faecalibacterium prausnitzii, Akkermansia muciniphila, and a lower Firmicutes/Bacteroidetes ratio, and their metabolites (short-chain fatty acids, bile acids, trimethylamine N-oxide) correlate with liver inflammation and fibrosis. Endocrine imbalances of cortisol, testosterone, and thyroid hormones further stratify metabolic vulnerability. Ultimately, multi-omics platforms (i.e., transcriptomics, lipidomics, proteomics, metabolomics, epigenomics) can reveal distinct molecular signatures that predict steatohepatitis, fibrogenesis, and early hepatocellular carcinoma. Integrating these biomarkers enables phase-specific enrichment strategies, earlier intervention windows, adaptive dose-finding, and mechanism-based endpoints in ALD trials. Remaining challenges include assay standardization, validation across diverse cohorts, and incorporation into regulatory frameworks. Future work could evaluate cost-effectiveness and feasibility in routine clinical practice. Widespread adoption promises earlier diagnosis, personalized risk reduction, and more efficient drug development for this globally prevalent disorder.
Background/Aims Endoplasmic reticulum (ER) stress in hepatocytes plays a causative role in alcohol-associated liver disease (ALD). The incomplete inhibition of ER stress by targeting canonical ER stress sensor proteins suggests the existence of noncanonical ER stress pathways in ALD pathology. This study aimed to delineate the role of RAB25 in ALD and its regulatory mechanism in noncanonical ER stress pathways.
Methods RAB25 activation was examined in liver samples from ALD patients and ethanol-fed mice. The interaction between RAB25 and GCN1 was confirmed through mass spectrometry and co-immunoprecipitation (Co-IP) assays in vitro. The role of RAB25/GCN1 in promoting noncanonical ER stress in ALD was assessed both in vitro and in vivo.
Results RAB25 expression was upregulated and specifically accumulated on the ER in ALD. Mass spectrometry and Co-IP assays confirmed that RAB25 interacts with GCN1, thereby activating a noncanonical ER stress pathway that facilitates ALD progression. Further analysis revealed that RAB25 interaction with GCN1 inhibits K33-ubiquitination-mediated degradation of GCN1, promotes GCN2 phosphorylation, and subsequently activates ATF4-mediated ER stress. This activation modulates lipid metabolism, mitochondrial function, and inflammation, thereby facilitating ALD progression. Knockdown of RAB25 in hepatocytes inhibited ER stress activation and mitigated associated mitochondrial dysfunction, excessive lipid synthesis, and the exaggerated inflammatory response in an ALD model.
Conclusions Our findings demonstrate a causal role for RAB25-GCN1 signaling in activating the ER stress pathway, which contributes to ALD progression. This pathway may provide a proof-of-concept target for treating ALD and associated metabolic disorders.
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
Hidden Burden of Alcohol Use Disorder in MASLD and MetALD: Clinical and Nomenclatural Implications Yuri Cho Gut and Liver.2025; 19(5): 637. CrossRef
Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab
Clin Mol Hepatol 2025;31(2):525-547. Published online January 9, 2025
Background/Aims Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.
Methods We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
Results In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Conclusions Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
Citations
Citations to this article as recorded by
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2026; 8(1): 101646. CrossRef
An Integrated Systematic Review and Meta‐Analysis From the Bloodstream to Identify Potential Biomarkers for ALD, MASLD, and HCC Without a Viral Background Karina González‐García, Cecilia Zertuche‐Martínez, Itayetzi Reyes‐Avendaño, Edilburga Reyes‐Jiménez, Pablo Muriel, Saúl Villa‐Treviño, Jaime Arellanes‐Robledo, Rafael Baltiérrez‐Hoyos, Verónica Rocío Vásquez‐Garzón Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021. Authors' Reply Pojsakorn Danpanichkul, Donghee Kim, Markos Kalligeros, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 1080. CrossRef
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, Cynthia Valério, Rodrigo Oliveira Moreira, Mónica Acevedo, Javier Brahm, Nelia Hernández, Adrian Gadano, Claudia P. O Annals of Hepatology.2025; 30(2): 101903. CrossRef
Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy, and Addiction Management. Authors' Reply Luis Antonio Díaz, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 61(7): 1256. CrossRef
Implementing public health policy to tackle alcohol-related harms Pojsakorn Danpanichkul, Karn Wijarnpreecha The Lancet Public Health.2025; 10(5): e350. CrossRef
Alcohol-Associated Liver Disease and Risk Stratification for Hepatocellular Carcinoma: A Comprehensive Review Jaeyoun Choi, Hyun-seok Kim Current Hepatology Reports.2025;[Epub] CrossRef
Public Health Policies and Strategies to Prevent Alcohol-Related Morbidity and Mortality Roba El Zibaoui, Luis Antonio Díaz, Francisco Idalsoaga, Juan Pablo Arab Current Hepatology Reports.2025;[Epub] CrossRef
Tetramethylpyrazine: A fermented alcohol product that mitigates alcoholic liver disease in mice Qing Pu, Han Gao, Dake Xiao, Manyuan Wang, Zhiyun Yang, Qiang He, Min Liu, Xuejin Zhu, Tao Pan, Zhitao Ma, Jiabo Wang, Yao Liu Free Radical Biology and Medicine.2025; 236: 160. CrossRef
Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020) Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanida Auttapracha, Shu-Yen Chan, Do Han Kim, Thanawin Pramotedham, Kanita Mankan, Chanokporn Puchongmart, Juan Pablo Arab, Luis Antonio Diaz, Jorge D. Machicado, Michael B. Wallace, Karn Wijarnpreecha Pancreatology.2025; 25(4): 508. CrossRef
Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease Luis Antonio Díaz, Summer Collier, Jeffrey Yin, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 62(7): 692. CrossRef
Osteoporosis is associated with increased CVD mortality and all-cause mortality in alcohol-consuming individuals: A cohort study using data from NHANES Xiaoqin Qu, Jingcheng Jiang, Qian Wu, PLOS One.2025; 20(6): e0327180. CrossRef
Fabrication of camptothecin and gold nanoparticles encapsulated liposomes for synergic anticancer therapy in liver cancer cells Hengyang Wang, Jingjian Ding, Tao Wang, Kongliang Luo Particulate Science and Technology.2025; 43(6): 1002. CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul Liver International.2025;[Epub] CrossRef
Social determinants of alcohol and tobacco use among Hispanic adolescents: a scoping review Kazi Priyanka Silmi, Victoria Castillo, Nallely Segura, Nayeli Carrillo Cervantes, Yailene Perez, Aubrey Valenzuela, Erika A. Pugh, Jennifer B. Unger, Marybel R. Gonzalez Frontiers in Psychiatry.2025;[Epub] CrossRef
MetALD: new insights and unraveling therapeutic potential Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis Bernardo de Faria Moraes, Gabriel André Pedral Diniz Leite, Gustavo André Pedral Diniz Leite, Igor Boechat Silveira, Nathália Veloso Lana, Guilherme Grossi Lopes Cançado Drug and Alcohol Dependence.2025; 275: 112840. CrossRef
Portal hypertension in alcohol-associated hepatitis: harmless and the reflection of systemic inflammation? Karim Gebara, Lionel Moulis, Joana Pissarra, Benjamin Rivière, Georges-Philippe Pageaux, José Ursic-Bedoya Clinics and Research in Hepatology and Gastroenterology.2025; 49(8): 102668. CrossRef
Patterns and Outcomes of Alcoholic Liver Disease (ALD) in Oman: A Retrospective Study in a Culturally Conservative Context Said A. Al-Busafi, Thuwiba A. Al Baluki, Ahmed Alwassief Livers.2025; 5(3): 38. CrossRef
Alcoholic liver disease: Mechanistic insights and therapeutic potential of traditional Chinese medicine through preclinical and clinical evidence Ke Wu, Long Zhao, Tiangang Wang, Jiayue Yang, Yueshui Zhao, Fukuan Du, Yu Chen, Shuai Deng, Jing Shen, Zhangang Xiao, Jingwen Liu, Ruhan Yang, Xi Li, Hua Li, Wanping Li, Xiaobing Li, Yuhong Sun, Li Gu, Xu Wu, Mingxing Li Journal of Ethnopharmacology.2025; 353: 120465. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Comparative effectiveness of digital versus face-to-face cognitive behavioral therapy for alcohol use disorder: a systematic review and meta-analysis Ji Eun Kim, Jiyeong Kim, Nayeon Choi, Sang Kyu Lee, Hong Seok Oh, Sungwon Roh Psychological Medicine.2025;[Epub] CrossRef
Alcohol use and cirrhosis in women: An underestimated risk P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef
A Higher Risk of Liver Cancer in Alcoholic Fatty Liver Disease than in Non-Alcoholic Fatty Liver Disease: an Analysis of the TriNetX Dabatase Ling-Hui Chang, Sheng-You Su, Chun Lee, Chao-Yu Hsu Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply Luis Antonio Díaz, Rohit Loomba Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1241. CrossRef
Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications Luyuan Chang, Yang Liu, Haipeng Li, Jiaqi Yan, Wenzong Wu, Nuo Chen, Chunyu Ma, Xinyi Zhao, Juan Chen, Jing Zhang Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
Longitudinal Risk of Cirrhosis by Steatotic Liver Disease Subtype Among 1.5 Million Individuals in the U.S. Mai Sedki, Zeyuan Yang, Ashwani K. Singal, Mário Guimarães Pessoa, Aleksander Krag, Jörn M. Schattenberg, Linda Henry, Saleh Alqahtani, Jeffrey V. Lazarus, Zobair M. Younossi, Robert J. Wong JHEP Reports.2025; : 101680. CrossRef
Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease Wei Zhang, Soo Young Hwang, Jay Luther Current Gastroenterology Reports.2025;[Epub] CrossRef
A multi-omics approach combining causal inference and in vivo validation identifies key protein drivers of alcohol-associated liver disease Qingyi Zhou, Xuan Ma, Qianqian Cui, Lei Zhang, Chao Yao, Zilu Zhang, Xiaoli Wang, Liang Chu Frontiers in Immunology.2025;[Epub] CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha Digestive Diseases and Sciences.2025;[Epub] CrossRef
Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy Afreen Usmani, Mohd Aftab Siddiqui, Anuradha Mishra, Rania I.M. Almoselhy, Ambreen Shoaib, Mirunalini Gobinath, Mohd Nazam Ansari Medical Oncology.2025;[Epub] CrossRef
Background/Aims Alcohol-associated liver disease (ALD) is a public health concern. ALD patients often have psychiatric comorbidities, but the effects of psychiatric interventions on ALD are not well-established. This study explores the prognostic impact of psychiatric intervention on ALD within UK Biobank cohort.
Methods This population-based study included 2,417 ALD patients from the UK Biobank cohort. Psychiatric intervention was defined by a consultation with psychiatrists during hospitalization or a history of medication related to alcohol use disorder and psychiatric comorbidities. Survival analysis was conducted, incorporating propensity score matching (PSM), to precisely assess the impact of psychiatric intervention.
Results Among 2,417 ALD patients, those with F10 (mental disorders due to alcohol) codes had poorer survival outcomes. Psychiatric intervention significantly improved the outcomes of both all-cause and liver-related mortality and reduced the incidence of liver cirrhosis. In subgroup or 2-year landmark analyses, psychiatric intervention consistently showed a survival benefit in ALD patients. In the multivariate analysis, psychiatric intervention was identified as a favorable prognostic factor (hazard ratio, 0.780; P=0.002 after PSM).
Conclusions This study demonstrates the favorable effect of psychiatric intervention in ALD patients with psychiatric comorbidities. These findings emphasize the importance of integrated management for ALD patients to address both their medical and psychiatric aspects. Therefore, we suggest the potential benefits of early psychiatric interventions in improving survival outcomes in ALD.
Citations
Citations to this article as recorded by
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study” Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2025; 31(1): 316. CrossRef
Trends in Concurrent Psychiatric Comorbidities in Alcohol-Associated Liver Disease: A Nationwide Study from 2015–2023 Shu-Yen Chan, Yee Hui Yeo, Hyunseok Kim, Molly Delk, Natchaya Polpichai, Pojsakorn Danpanichkul, Peng-Sheng Ting Digestive Diseases and Sciences.2025;[Epub] CrossRef
Alcohol-associated intestinal dysbiosis and bacterial overgrowth can lead to a dysregulation of tryptophan metabolism and lower production of indoles. Several of these indole derivatives are aryl hydrocarbon receptor ligands that, in turn, are involved in antimicrobial defense via induction of interleukin-22 (IL-22). IL-22 increases the expression of intestinal regenerating islet-derived 3 (Reg3) lectins, which maintain low bacterial colonization of the inner mucus layer and reduce bacterial translocation to the liver. Chronic alcohol consumption is associated with reduced intestinal expression of Reg3β and Reg3γ, increased numbers of mucosa-associated bacteria and bacterial translocation. Translocated microbial products and viable bacteria reach the liver and activate the innate immune system. Release of inflammatory molecules promotes inflammation, contributes to hepatocyte death and results in a fibrotic response. This review summarizes the mechanisms by which chronic alcohol intake changes the gut microbiota and contributes to alcohol-associated liver disease by changing microbial-derived metabolites.
Citations
Citations to this article as recorded by
Selective Depletion of Gut Gram-Negative Bacteria Attenuates Alcohol Binge-Induced Cardiovascular Dysfunction by Lowering Cardiac Anandamide Levels Sarah E. Cohen, Meagan E. Donovan, Davin J. Gardner, Danielle Sambo, Seray B. Karagoz, Resat Cinar, David Goldman, Jason D. Gardner, Pal Pacher, Janos Paloczi The American Journal of Pathology.2026; 196(1): 192. CrossRef
Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway Jin-Ju Jeong, Yoo-Jeong Jin, Raja Ganesan, Hee Jin Park, Byeong Hyun Min, Min Kyo Jeong, Sang Jun Yoon, Mi Ran Choi, Satya Priya Sharma, You Jin Jang, Uigi Min, Jong-Hyun Lim, Kyeong Min Na, Jieun Choi, Sang Hak Han, Young Lim Ham, Do Yup Lee, Byung-Yong Probiotics and Antimicrobial Proteins.2025; 17(5): 2894. CrossRef
Treating chronic stress and chronic pain by manipulating gut microbiota with diet: can we kill two birds with one stone? Alessia Costa, Elena Lucarini Nutritional Neuroscience.2025; 28(2): 221. CrossRef
Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial Do Seon Song, Jin Mo Yang, Young Kul Jung, Hyung Joon Yim, Hee Yeon Kim, Chang Wook Kim, Soon Sun Kim, Jae Youn Cheong, Hae Lim Lee, Sung Won Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Annals of Hepatology.2025; 30(1): 101749. CrossRef
Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications” Soon Kyu Lee, Jong Young Choi Clinical and Molecular Hepatology.2025; 31(1): 301. CrossRef
Lactobacillus rhamnosus GG Combined with Metformin Alleviates Alcohol-Induced Liver Inflammation in Mice by Maintaining the Intestinal Barrier and Regulating Treg/Th1 Cells Yin Zhu, Yizhi Pan, Xiaozhi Wang, Li Wei, Lujian Zhu, Yu Guo, HaoRan Jin, Yingying Gu, Yaqin Wang, Yongping Chen, Lanman Xu Journal of Medicinal Food.2025; 28(4): 354. CrossRef
Role of Kynurenine and Its Derivatives in Liver Diseases: Recent Advances and Future Clinical Perspectives Qiwen Tan, Shenghe Deng, Lijuan Xiong International Journal of Molecular Sciences.2025; 26(3): 968. CrossRef
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors Francisco Capinha, Sofia Carvalhana, Helena Cortez-Pinto Digestive Diseases and Sciences.2025; 70(5): 1746. CrossRef
NLRP3 and Gut–Liver Axis: New Possibility for the Treatment of Alcohol‐Associated Liver Disease Lu Dong, Haotian Zhang, Yanyu Kang, Fei Wang, Ting Bai, Yong Yang Journal of Gastroenterology and Hepatology.2025; 40(5): 1070. CrossRef
Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut–Liver Axis in Alcohol-Associated Disease Beom Sun Chung, Keungmo Yang, Chihyun Park, Tom Ryu International Journal of Molecular Sciences.2025; 26(12): 5442. CrossRef
Ferroptosis and gut microbiota: A new horizon in alcohol-associated liver disease management Yue Chen, Wenkang Gao, Kailin Cai, Ling Yang, Huikuan Chu Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
Inflammation and Necrosis Syndrome in Young Piglets—A Longitudinal Study Sabrina Becker, Katrin Hindenlang, Josef Kuehling, Mirjam Lechner, Gerald Reiner Veterinary Sciences.2025; 12(8): 752. CrossRef
Synergistic toxicity in alcohol-associated liver disease and PFAS exposure Arthur D Stem, Ricardo Scheufen Tieghi, Vaia Lida Chatzi, Nicole Kleinstreuer, Damaskini Valvi, David C Thompson, Vasilis Vasiliou Toxicological Sciences.2025; 208(1): 9. CrossRef
Sex-Specific Effect of Ethanol on Colon Content Lipidome in a Mice Model Using Nontargeted LC/MS Jayashankar Jayaprakash, Siddabasave Gowda B. Gowda, Pradeep K. Shukla, Divyavani Gowda, Lipsa Rani Nath, Hitoshi Chiba, Radhakrishna Rao, Shu-Ping Hui ACS Omega.2024; 9(14): 16044. CrossRef
Lactobacillus helveticus attenuates alcoholic liver injury via regulation of gut microecology in mice Jiawen Lv, Guanjing Lang, Qiangqiang Wang, Wenlong Zhao, Ding Shi, Ziyuan Zhou, Yangfan Shen, He Xia, Shengyi Han, Lanjuan Li Microbial Biotechnology.2024;[Epub] CrossRef
Gut microbiome and metabolome signatures in liver cirrhosis-related complications Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, G Clinical and Molecular Hepatology.2024; 30(4): 845. CrossRef
Mapping the relationship between alcohol use disorder and gut microbiota: a 20-year bibliometric study Ao Xiang, Yonglong Chang, Li Shi, Xuhui Zhou Frontiers in Microbiology.2024;[Epub] CrossRef
Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease Hui Gao, Yanchao Jiang, Ge Zeng, Nazmul Huda, Themis Thoudam, Zhihong Yang, Suthat Liangpunsakul, Jing Ma eGastroenterology.2024; 2(4): e100104. CrossRef
Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining Akkermansia muciniphila in alcoholic steatohepatitis Liuyi Hao, Wei Zhong, Jongmin Woo, Xiaoyuan Wei, Hao Ma, Haibo Dong, Wei Guo, Xinguo Sun, Ruichao Yue, Jiangchao Zhao, Qibin Zhang, Zhanxiang Zhou Hepatology.2023; 78(3): 896. CrossRef
TRPV6 deficiency attenuates stress and corticosterone-mediated exacerbation of alcohol-induced gut barrier dysfunction and systemic inflammation Avtar S. Meena, Pradeep K. Shukla, Rupa Rao, Cherie Canelas, Joseph F. Pierre, RadhaKrishna Rao Frontiers in Immunology.2023;[Epub] CrossRef
Soy Lecithin in High‐Fat Diets Exerts Dual Effects on Adipose Tissue Versus Ileum Charline Buisson, Valentin Leuzy, Emmanuelle Loizon, Emmanuelle Meugnier, Magali Monnoye, Catherine Philippe, Philippe Gérard, Marie‐Caroline Michalski, Fabienne Laugerette Molecular Nutrition & Food Research.2023;[Epub] CrossRef
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis Xuanxuan Niu, Lin Zhu, Yifan Xu, Menghan Zhang, Yanxu Hao, Lei Ma, Yan Li, Huichun Xing BMC Public Health.2023;[Epub] CrossRef
Circadian rhythms and inflammatory diseases of the liver and gut Jessica M. Ferrell Liver Research.2023; 7(3): 196. CrossRef
The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics K. P. Divya, Parneet Hari, Navjot Kanwar, Navita Aggarwal, Preeti Singh Dhoat, Lu Liu, Abhinav Kanwal, Shailendra Pratap Singh, Jiong Yu Advanced Gut & Microbiome Research.2023; 2023: 1. CrossRef
The Protective Effect of Auricularia cornea var. Li. Polysaccharide on Alcoholic Liver Disease and Its Effect on Intestinal Microbiota Tianci Wang, Zikun Jia, Canghai An, Ping Ren, Yiting Yang, Wanting Wang, Ling Su Molecules.2023; 28(24): 8003. CrossRef
Gut liver brain axis in diseases: the implications for therapeutic interventions Mengyao Yan, Shuli Man, Benyue Sun, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
Gut Barrier and Microbiota in Cirrhosis Cyriac A. Philips, Philip Augustine Journal of Clinical and Experimental Hepatology.2022; 12(2): 625. CrossRef
Probiotics attenuate alcohol-induced muscle mechanical hyperalgesia: Preliminary observations Paul G Green, Pedro Alvarez, Jon D Levine Molecular Pain.2022;[Epub] CrossRef
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do Biomedicines.2022; 10(3): 550. CrossRef
Immune Response of an Oral Enterococcus faecalis Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease Beatriz Garcia Mendes, Yi Duan, Bernd Schnabl Viruses.2022; 14(3): 490. CrossRef
A novel ladderlectin from hybrid crucian carp possesses antimicrobial activity and protects intestinal mucosal barrier against Aeromonas hydrophila infection Chen Feng, Xiaofeng Liu, Yiyang Tang, Mengzhe Feng, Zejun Zhou, Shaojun Liu Fish & Shellfish Immunology.2022; 124: 1. CrossRef
Principles of diagnosis and treatment of alcohol-induced liver fibrosis D. V. Garbuzenko Meditsinskiy sovet = Medical Council.2022; (7): 104. CrossRef
Gut Microbiota Regulation of AHR Signaling in Liver Disease Baohong Wang, Ziyuan Zhou, Lanjuan Li Biomolecules.2022; 12(9): 1244. CrossRef
Pathophysiological Prerequisites and Therapeutic Potential of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis D. V. Garbuzenko The Russian Archives of Internal Medicine.2022; 12(5): 352. CrossRef
Trimethylamine N-Oxide (TMAO) and Indoxyl Sulfate Concentrations in Patients with Alcohol Use Disorder Laurent Coulbault, Alice Laniepce, Shailendra Segobin, Céline Boudehent, Nicolas Cabé, Anne Lise Pitel Nutrients.2022; 14(19): 3964. CrossRef
Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver Haripriya Gupta, Ki Tae Suk, Dong Joon Kim Journal of Clinical Medicine.2021; 10(3): 541. CrossRef
Intestinal Barrier in Human Health and Disease Natalia Di Tommaso, Antonio Gasbarrini, Francesca Romana Ponziani International Journal of Environmental Research and Public Health.2021; 18(23): 12836. CrossRef
Interleukin-17 in Liver Disease Pathogenesis Na Li, Gen Yamamoto, Hiroaki Fuji, Tatiana Kisseleva Seminars in Liver Disease.2021; 41(04): 507. CrossRef
REG3α is a novel biomarker that potentially correlates with acute allograft rejection after intestinal transplantation Carolyn P. Smullin, Robert S. Venick, Elizabeth A. Marcus, Bita V. Naini, Douglas G. Farmer Clinical Transplantation.2021;[Epub] CrossRef
First
Prev
